Evidence map›Paper›PMID 37779059›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Bile Duct Mixed Neuroendocrine-nonendocrine Neoplasm with a Complete Response to Chemoradiotherapy.

Yosuke Horita, Yoshiaki Mihara, Masafumi Mizuide, Shin-Ei Noda, Tomonori Kawasaki, Masanori Yasuda, Shingo Kato, Shomei Ryozawa, Tetsuya Hamaguchi

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Mixed Neuroendocrine-Non-Neuroendocrine Tumor of Bile Duct.The Kaohsiung journal of medical sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yosuke HoritaDepartment of Medical Oncology, Saitama Medical University International Medical Center, Japan.
Yoshiaki MiharaDepartment of Medical Oncology, Saitama Medical University International Medical Center, Japan.
Masafumi MizuideDepartment of Gastroenterology, Saitama Medical University International Medical Center, Japan.
Shin-Ei NodaDepartment of Radiation Oncology, Saitama Medical University International Medical Center, Japan.
Tomonori KawasakiDepartment of Pathology, Saitama Medical University International Medical Center, Japan.
Masanori YasudaDepartment of Pathology, Saitama Medical University International Medical Center, Japan.
Shingo KatoDepartment of Radiation Oncology, Saitama Medical University International Medical Center, Japan.
Shomei RyozawaDepartment of Gastroenterology, Saitama Medical University International Medical Center, Japan.
Tetsuya HamaguchiDepartment of Medical Oncology, Saitama Medical University International Medical Center, Japan.
Saitama Medical University · JPSaitama International Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence of neuroendocrine carcinomas arising from the bile duct is low, and that of mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) is even lower; therefore, there is no standard treatment for MiNENs. Choosing the appropriate treatment in clinical practice is difficult. We herein report a case of unresectable extrahepatic bile duct MiNEN in a 66-year-old man who received curative chemoradiotherapy and achieved a complete response, remaining recurrence-free for 2.5 years. We consider the findings of this case to be valuable in selecting a treatment strategy for unresectable bile duct MiNENs.

Indexed as

Bile Duct NeoplasmsChemoradiotherapyAgedCarcinoma, NeuroendocrineHumansMaleNeuroendocrine TumorsTreatment Outcomebile duct cancerchemoradiotherapymixed neuroendocrine-nonendocrine neoplasm (MiNEN)neuroendocrine cancer

Identifiers

PMID37779059
PMCPMC11116019
OpenAlexW4387123325

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.